News
Lilly licenses Hanmi GLP-2 drug in $1.26bn deal
Eli Lilly's relentless pipeline-building drive has continued with a licensing deal for Hanmi's sonefpeglutide, in phase 2 for short bowel syndrome.
Monday 31 August 2026
